SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy

SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy

Background: Elevated myocardial intracellular sodium ([Na+]i) was shown to decrease mitochondrial calcium ([Ca2+]MITO) via mitochondrial sodium/calcium exchanger (NCXMITO), resulting in decreased mitochondrial ATP synthesis. The sodium-glucose co-transporter 2 inhibitor (SGLT2i) ertugliflozin (ERTU)...

Full description

Bibliographic Details
Main Authors: Dominique Croteau, Tomas Baka, Sara Young, Huamei He, Jordan M. Chambers, Fuzhong Qin, Marcello Panagia, David R. Pimentel, James A. Balschi, Wilson S. Colucci, Ivan Luptak
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Cardiac energetics
Contractile function
Diabetic cardiomyopathy
Ertugliflozin
Myocardial intracellular sodium
Sodium-glucose co-transporter 2 (SGLT2) inhibitor
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332223000987

Internet

http://www.sciencedirect.com/science/article/pii/S0753332223000987

Similar Items